Search alternatives:
canadian » canada (Expand Search)
Showing 1 - 20 results of 284 for search 'Canadian Agency for Drugs and Technologies in Health,', query time: 0.20s Refine Results
  1. 1
    Identification of tuberculosis : a review of the guidelines

    Identification of tuberculosis : a review of the guidelines by Brett, Kendra, Dulong, Camille, Severn, Melissa

    Ottawa : Canadian Agency for Drugs and Technologies in Health, 2020
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  2. 2
    Adapted or tailored psychological interventions for treating women with mental illness : a review of clinical effectiveness and guidelines

    Adapted or tailored psychological interventions for treating women with mental illness : a review of clinical effectiveness and guidelines by Williams, D. (Dinsie), Mierzwinski-Urban, Monika

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
    Version: 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Full text
    Save to List
    Saved in:
  3. 3
    Common drug review new combination product submission : Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza) : (Janssen Canada Inc.).

    Common drug review new combination product submission : Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza) : (Janssen Canada Inc.).

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  4. 4
    CHAD65 and CHA2DS2-VASc risk stratification tools for patients with atrial fibrillation : a review of clinical effectiveness and guidelines

    CHAD65 and CHA2DS2-VASc risk stratification tools for patients with atrial fibrillation : a review of clinical effectiveness and guidelines by Banerjee, Srabani, Picheca, Lory

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Save to List
    Saved in:
  5. 5
    Clinical review report. Dexamethasone (Ozurdex) (Allergan, Inc.) : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic.

    Clinical review report. Dexamethasone (Ozurdex) (Allergan, Inc.) : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic.

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  6. 6
    Ustekinumab (Stelara) injection.

    Ustekinumab (Stelara) injection.

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2016
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Save to List
    Saved in:
  7. 7
    Pharmacoeconomic review report. Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability.

    Pharmacoeconomic review report. Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  8. 8
    Physical activity for chronic osteoarthritic knee pain : a review of clinical effectiveness

    Physical activity for chronic osteoarthritic knee pain : a review of clinical effectiveness by Peprah, Kwakye, Argáez, Charlene

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  9. 9
    Golimumab (Simponi) (subcutaneous injection) : adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, or have medical contraindications for, conventional therapies.

    Golimumab (Simponi) (subcutaneous injection) : adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, or have medical contrain...

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2014
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Save to List
    Saved in:
  10. 10
    Concurrent treatment for substance use disorder and trauma-related comorbidities : a review of clinical effectiveness and guidelines

    Concurrent treatment for substance use disorder and trauma-related comorbidities : a review of clinical effectiveness and guidelines by Banerjee, Srabani, Spry, Carolyn

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
    Version: 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Full text
    Save to List
    Saved in:
  11. 11
    Imiquimod for the treatment of genital warts : a review of clinical effectiveness and cost-effectiveness

    Imiquimod for the treatment of genital warts : a review of clinical effectiveness and cost-effectiveness by Banerjee, Srabani, Kaunelis, David

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Full text
    Save to List
    Saved in:
  12. 12
    CADTH Canadian Drug Expert Committee recommendation. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features.

    CADTH Canadian Drug Expert Committee recommendation. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Full text
    Get full text
    Full text
    Get full text
    Full text
    Save to List
    Saved in:
  13. 13
    Nicotine replacement therapy for smoking cessation or reduction : review of the clinical evidence

    Nicotine replacement therapy for smoking cessation or reduction : review of the clinical evidence

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2014
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Save to List
    Saved in:
  14. 14
    CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.

    CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.

    [Ottawa, Ontario] : Canadian Agency for Drugs and Technologies in Health, 2017
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Full text
    Save to List
    Saved in:
  15. 15
    Patient group input submissions. Selexipag (Uptravi) for pulmonary arterial hypertension (WHO class II and III).

    Patient group input submissions. Selexipag (Uptravi) for pulmonary arterial hypertension (WHO class II and III).

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Full text
    Save to List
    Saved in:
  16. 16
    CADTH Canadian Drug Expert Committee recommendation. Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD).

    CADTH Canadian Drug Expert Committee recommendation. Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  17. 17
    Continuously diffused oxygen therapy for wound healing : a review of the clinical effectiveness, cost-effectiveness, and guidelines

    Continuously diffused oxygen therapy for wound healing : a review of the clinical effectiveness, cost-effectiveness, and guidelines by Edge, Rob, Frey, Nina

    Ottawa : Canadian Agency for Drugs and Technologies in Health, 2020
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  18. 18
    Immediately sequential bilateral cataract surgery for the treatment of bilateral cataracts : a review of safety and guidelines

    Immediately sequential bilateral cataract surgery for the treatment of bilateral cataracts : a review of safety and guidelines by Li, Yan (Clinical research officer), Butcher, Robyn

    Ottawa : Canadian Agency for Drugs and Technologies in Health, 2020
    Version 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  19. 19
    Serial X-ray radiography for the diagnosis of osteomyelitis : a review of diagnostic accuracy, clinical utility, cost-effectiveness, and guidelines

    Serial X-ray radiography for the diagnosis of osteomyelitis : a review of diagnostic accuracy, clinical utility, cost-effectiveness, and guidelines by Tran, Khai, active 2010, Mierzwinski-Urban, Monika

    Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020
    Version: 1.0.
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Full text
    Save to List
    Saved in:
  20. 20
    High-dose stimulants for attention-deficit/hyperactivity disorder : a review of the clinical effectiveness, safety and guidelines

    High-dose stimulants for attention-deficit/hyperactivity disorder : a review of the clinical effectiveness, safety and guidelines

    [Ottawa] : Canadian Agency for Drugs and Technologies in Health, 2016
    “…Canadian Agency for Drugs and Technologies in Health,…”
    Format: Electronic eBook
    Get full text
    Full text
    Save to List
    Saved in:

Search Tools: